The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib are indicated as second-line treatment for chronic myeloid leukemia resistant or intolerant to the current first-line TKI imatinib. These are agents are well tolerated, but potent and as such should be monitored for potentially serious side-effects like fluid retention and pleural effusions. Here we present key clinical trial data and safety considerations for all FDA approved TKIs in context for effective management of fluid retention and pleural effusions. Altering the dasatinib regimen from 70 mg twice daily to 100 mg daily reduces the risk of pleural effusion for patients taking dasatinib. Should pleural effusion develop, dasatinib should be interrupted until the condition resolves. Patients with a history of pleural effusion risk factors should be monitored closely while taking dasatinib. Patients receiving imatinib and nilotinib are not without risk of fluid retention. All patients should also be educated to recognize and report key symptoms of fluid retention or pleural effusion. Pleural effusions are generally managed by dose interruption/reduction and other supportive measures in patients with chronic myeloid leukemia receiving dasatinib therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intermittent dosing regimens have the benefit of reducing the risk of associated medication side effects, which could include D-associated myelosuppression, fluid retention, hemorrhage, difficulty breathing, and myocardial dysfunction (44).”
From Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial (2022) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 1×
“In the pivotal phase III study of imatinib, 23% of patients faced initial, inherent (primary) resistance, and a further 4% of patients presented with intolerance to the agent [ 9 ,10].”
BackgroundBenson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
GROFFEN, J., STEPHENSON, J., HEISTERKAMP, N., DEKLEIN, A., BARTRAM, C., & GROSVELD, G. (1984) · Cell · doi:10.1016/0092-8674(84)90077-1 · Cited by 1,599
Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281 · cited 11×
“This genetic abnormality results from a reciprocal translocation between chromosomes 9 and 22, leading to the formation of the pathogenic tyrosine kinase signal transduction protein, BCR-ABL [4-6].”
BackgroundInfluentialO'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036 · cited 1×
“This agent has 325fold greater activity against unmutated BCR-ABL in vitro than imatinib, and displays activity in all but one of the known imatinib-resistant BCR-ABL mutations (i.e., T315I) [ 15-17 ].”
BackgroundBartram, C. R., de Klein, A., Hagemeijer, A., van Agthoven, T., van Kessel, A. G., Bootsma, D., Grosveld, G., Ferguson-Smith, M. A., Davies, T., Stone, M., et al. (1983) · Nature · doi:10.1038/306277a0 · Cited by 747 · cited 1×
“This genetic abnormality results from a reciprocal translocation between chromosomes 9 and 22, leading to the formation of the pathogenic tyrosine kinase signal transduction protein, BCR-ABL [4-6].”
BackgroundKantarjian, H. M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Ossenkoppele, G. J., Nicolini, F.-E., O'Brien, S. G., Litzow, M., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080689 · Cited by 746 · cited 2×
“The activity of nilotinib (400 mg orally twice daily) in patients with all phases of CML resistant or intolerant to imatinib has been confirmed in phase II studies [ 30-32 ].”
BackgroundRix, U., Hantschel, O., Dürnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., et al. (2007) · Blood · doi:10.1182/blood-2007-07-102061 · Cited by 671 · cited 1×
“It has been suggested that dasatinib may inhibit the function of normal T cells [27], and bind major regulators of the immune system [28].”
BackgroundO'Hare, T., Eide, C. A., & Deininger, M. W. N. (2007) · Blood · doi:10.1182/blood-2007-03-066936 · Cited by 641 · cited 1×
“This agent has 325fold greater activity against unmutated BCR-ABL in vitro than imatinib, and displays activity in all but one of the known imatinib-resistant BCR-ABL mutations (i.e., T315I) [ 15-17 ].”
BackgroundHochhaus, A., Kantarjian, H. M., Baccarani, M., Lipton, J. H., Apperley, J. F., Druker, B. J., Facon, T., Goldberg, S. L., Cervantes, F., Niederwieser, D., et al. (2007) · Blood · doi:10.1182/blood-2006-09-047266 · Cited by 609 · cited 5×
“The Toxicities of Dasatinib The side effects associated with dasatinib therapy are predominantly mild or moderate (grade 1 or 2 by the National Cancer Institute Cancer Therapy Evaluation Program criteria), and are self-limiting or resolve following supportive care [18-20,22].”
BackgroundInfluentialShah, N. P., Kantarjian, H. M., Kim, D.-W., Réa, D., Dorlhiac-Llacer, P. E., Milone, J. H., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Charbonnier, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9260 · Cited by 489 · cited 4×
“After a minimum follow-up of 6 months, major cytogenetic responses were attained in 59% of patients receiving dasatinib 100 mg once daily and in 55% of patients receiving dasatinib 70 mg twice daily [22].”
BackgroundResultInfluentialCortes, J., Rousselot, P., Kim, D.-W., Ritchie, E., Hamerschlak, N., Coutre, S., Hochhaus, A., Guilhot, F., Saglio, G., Apperley, J., et al. (2007) · Blood · doi:10.1182/blood-2006-09-046888 · Cited by 416 · cited 4×
“The Toxicities of Dasatinib The side effects associated with dasatinib therapy are predominantly mild or moderate (grade 1 or 2 by the National Cancer Institute Cancer Therapy Evaluation Program criteria), and are self-limiting or resolve following supportive care [18-20,22].”
BackgroundInfluentialQuintás-Cardama, A., Kantarjian, H., O'Brien, S., Borthakur, G., Bruzzi, J., Munden, R., & Cortes, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0329 · Cited by 388 · cited 4×
“Factors significantly related to the development of pleural effusion include a history of cardiac disease, hypertension, hypercholesterolemia, history of autoimmune disease, and history of skin rash during imatinib or dasatinib therapy [24,25].”
BackgroundInfluentialGuilhot, F., Apperley, J., Kim, D.-W., Bullorsky, E. O., Baccarani, M., Roboz, G. J., Amadori, S., de Souza, C. A., Lipton, J. H., Hochhaus, A., et al. (2007) · Blood · doi:10.1182/blood-2006-09-046839 · Cited by 371 · cited 4×
“Dasatinib is associated with correspondingly positive rates of treatment compliance and toxicity-related withdrawal [ 18-20 ,22].”
BackgroundInfluentialNew Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
Kantarjian, H. M., Talpaz, M., Giles, F., O'Brien, S., & Cortes, J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-12-200612190-00008 · Cited by 256 · cited 2×
“The most understood mechanism is mutation of BCR-ABL, preventing imatinib from binding effectively to the protein [8].”
BackgroundO'Brien, S., Berman, E., Borghaei, H., DeAngelo, D. J., Devetten, M. P., Devine, S., Erba, H. P., Gotlib, J., Jagasia, M., Moore, J. O., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0065 · Cited by 208
Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia: A Case Series
Bergeron, A., Réa, D., Levy, V., Picard, C., Meignin, V., Tamburini, J., Bruzzoni-Giovanelli, H., Calvo, F., Tazi, A., & Rousselot, P. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-715cr · Cited by 184 · cited 2×
“There is also evidence that pleural effusions may be immunerelated, as shown by lymphocytic infiltration of pleural fluids and an association between effusions and immunemediated reactions, such as rash and autoimmune events [24,26].”
BackgroundO’Brien, S. G., Guilhot, F., Goldman, J. M., Hochhaus, A., Hughes, T. P., Radich, J. P., Rudoltz, M., Filian, J., Gathmann, I., Druker, B. J., et al. (2008) · Blood · doi:10.1182/blood.v112.11.186.186 · Cited by 172
Molecular monitoring of BCR–ABL as a guide to clinical management in chronic myeloid leukaemia
Hughes, T., & Branford, S. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.01.008 · Cited by 158 · cited 1×
“In the pivotal phase III study of imatinib, 23% of patients faced initial, inherent (primary) resistance, and a further 4% of patients presented with intolerance to the agent [9,10].”
Backgroundde Lavallade, H., Punnialingam, S., Milojković, D., Bua, M., Khorashad, J. S., Gabriel, I. H., Chaidos, A., Olavarría, E., Goldman, J. M., Apperley, J. F., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07108.x · Cited by 141 · cited 3×
“Factors significantly related to the development of pleural effusion include a history of cardiac disease, hypertension, hypercholesterolemia, history of autoimmune disease, and history of skin rash during imatinib or dasatinib therapy [24,25].”
BackgroundBlake, S., Hughes, T. P., Mayrhofer, G., & Lyons, A. B. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.02.006 · Cited by 111 · cited 1×
“It has been suggested that dasatinib may inhibit the function of normal T cells [27], and bind major regulators of the immune system [28].”
BackgroundMauro, M. J., Baccarani, M., Cervantes, F., Lipton, J. H., Matloub, Y., Sinha, R., & Stone, R. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.7009 · Cited by 75
The Biology of Chronic Myelogenous Leukemia: Implications for Imatinib Therapy
Álvarez, R. H., Kantarjian, H. M., & Cortes, J. E. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2006.12.007 · Cited by 53 · cited 1×
“Even with the benefit of imatinib mesylate treatment, some patients with CML progress to BC [7].”
BackgroundFioretos, T. (2015) · Wiley eBooks · doi:10.1002/9781118795569.ch8 · Cited by 31
Khoury, H. J., Goldberg, S. L., Mauro, M. J., Stone, R. M., Matloub, Y., Chen, T., & Guilhot, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.7015 · Cited by 25
Ottmann, O. G., Kantarjian, H. M., Larson, R. A., le Courte, P., Baccarani, M., Rafferty, T. S., Weitzman, A., & Giles, F. J. (2006) · Blood · doi:10.1182/blood.v108.11.1862.1862 · Cited by 19
Management of Bcr–Abl-positive leukemias with dasatinib
Hochhaus, A. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.11.1529 · Cited by 16 · cited 1×
“If an immune-related mechanism is indeed responsible for pleural effusion occurring during dasatinib treatment, corticosteroids are likely to be more effective than diuretics as an adjunct to dose reduction/interruption [26,29].”
BackgroundImatinib use in chronic phase CML in clinical practice: the UNIC study
Steegmann, J. L., Michallet, M., Morra, E., Marín, D., Ossenkoppele, G. J., Verhoef, G., Kühr, T., Bjoreman, M., Sterckx, M., & Cerri, K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.7077 · Cited by 8
Research works printed but not linked: 2
- Le Coutre P Larson R Kantarjian H A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant or -intolerant patients with Philadelphia-positive chronic myelogenous leukemia in accelerated phase Haematologica 2007 92 suppl 1 557
- Ottmann O Larson R Kantarjian H Nilotinib monotherapy in patients with imatinib-resistant or -intolerant Ph+ chronic myelogenous leukemia (CML) in blast crisis or relapsed/refractory Ph+ acute lymphoblastic leukemia Haematologica 2007 92 suppl 1 556
Cited by
on behalf of the Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group, Kroschinsky, F., Stölzel, F., von Bonin, S., Beutel, G., Kochanek, M., Kiehl, M., & Schellongowski, P. (2017) · Critical Care · doi:10.1186/s13054-017-1678-1 · Cited by 500
Targeted therapies in pulmonary arterial hypertension
Montani, D., Chaumais, M.-C., Guignabert, C., Günther, S., Girerd, B., Jaïs, X., Algalarrondo, V., Price, L. C., Savale, L., Sitbon, O., et al. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.002 · Cited by 213
Gonzales, M. M., Garbarino, V. R., Marques Zilli, E., Petersen, R. C., Kirkland, J. L., Tchkonia, T., Musi, N., Seshadri, S., Craft, S., & Orr, M. E. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.62 · Cited by 203
“Intermittent dosing regimens have the benefit of reducing the risk of associated medication side effects, which could include D-associated myelosuppression, fluid retention, hemorrhage, difficulty breathing, and myocardial dysfunction (44).”
BackgroundFirst-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Wei, G., Rafiyath, S., & Liu, D. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-47 · Cited by 170
“Pleural effusion is rare with nilotinib and imatinib but is a more prominent side effect of dasatinib treatment [26,27].”
BackgroundPhillips, K. M., Pinilla-Ibarz, J. A., Sotomayor, E. M., Lee, M., Jim, H., Small, B. J., Sokol, L., Lancet, J. E., Tinsley, S., Sweet, K. L., et al. (2012) · Supportive Care in Cancer · doi:10.1007/s00520-012-1630-5 · Cited by 150
“For example, pleural effusions (of which dry cough, chest pain, and dyspnea could be symptoms) may be more common among patients taking dasatinib [23], rashes may be more common in those taking nilotinib [22], and gastrointestinal upset and edema may be more common among patients taking imatinib [22].”
Background
Metadata
- Authors
- Masiello, D., Gorospe, G., & Yang, A. S.
- Affiliations
- University of Southern California (US)
- Corresponding author
- Yang, Allen S
- Venue
- Journal of Hematology & Oncology
- Published
- 2009-11-12
- Volume
- 2
- Issue
- 1
- Pages
- 46-46
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC2785832
- OpenAlex
- W2120222130
- Cited by
- 66
- References
- 30
- Citations by year
- 2026: 3 · 2024: 1 · 2023: 3 · 2022: 6 · 2021: 6 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 6 · 2016: 2 · 2015: 8 · 2014: 2 · 2013: 4 · 2012: 8
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Kenneth T. and Eileen L. Norris Foundation
- Bristol-Myers Squibb
- Celgene
- Eisai
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- fluid retention, pleural effusion, dasatinib, tyrosine kinase inhibitors, chronic myeloid leukemia, nilotinib, imatinib, dose interruption, dose reduction, adverse drug reactions, second-line therapy
- MeSH terms
- Dasatinib, Algorithms, Humans, Pleural Effusion, Protein-Tyrosine Kinases, Pyrimidines, Thiazoles, Water-Electrolyte Imbalance, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Incidence, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Figure 1 The management of pleural effusion emerging on treatment with dasatinib. aBMS, 2009 [13]. bNCCN, 2009 [2]. Abbreviation: ANC = absolute neutrophil count](https://figures.cochat.ai/paper-figures/822752d4bb30437683441a24fcd3fe77/the-occurrence-and-management-of-fluid-retention-associated-with-tki-therapy-in-figure-1.jpg)